PE20090987A1 - PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE - Google Patents
PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDEInfo
- Publication number
- PE20090987A1 PE20090987A1 PE2008001380A PE2008001380A PE20090987A1 PE 20090987 A1 PE20090987 A1 PE 20090987A1 PE 2008001380 A PE2008001380 A PE 2008001380A PE 2008001380 A PE2008001380 A PE 2008001380A PE 20090987 A1 PE20090987 A1 PE 20090987A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- composition including
- glucoside
- derivative
- carbonitrile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE PIRAZOL-O-GLUCOSIDO DE FORMULA (I), EN COMBINACION CON UN INHIBIDOR DE DPP IV SELECCIONADO DE SITAGLIPTINA, VIDAGLIPTINA, SAXAGLIPTINA, ALOGLIPTINA, DENAGLIPTINA, (2S)-1-{[2-(5-METIL-2-FENILOXAZOL-4-IL)ETILAMINO]ACETIL}PIRROLIDIN-2-CARBONITRILO, (2S)-1-{[1,1-DIMETIL-3-(4-PIRIDIN-3-ILIMIDAZOL-1-IL)PROPILAMINO]ACETIL}PIRROLIDIN-2-CARBONITRILO; (S)-1-((2S, 3S, 11bS)-2-AMINO-9,10-DIMETOXI-1,3,4,7,11b-HEXAHIDRO-2H-PIRIDO[2,1-a]ISOQUINOLIN-3-IL)-4-FLUOROMETILPIRROLIDIN-2-ONA; ENTRE OTROS. DICHO COMPUESTO DE FORMULA (I) TIENE LOS SIGUIENTES SUSTITUYENTES: R1 ES ALCOXI C1-3; L1 Y L2 SON H O F Y R6 ES H, (ALQUIL C1-3)CARBONILO, (ALQUIL C1-6)OXICARBONILO, FENILOXICARBONILO, BENCILOXICARBONILO O BENCILCARBONILO. DICHA COMPOSICION ES ADECUADA PARA EL TRATAMIENTO O PREVENCION DE UNA O MAS AFECCIONES SELECCIONADAS DE DIABETES MELLITUS DE TIPO 1, DIABETES MELLITUS DE TIPO 2, TOLERANCIA ANORMAL A LA GLUCOSA, GLUCOSA SANGUINEA ANORMAL EN AYUNAS E HIPERGLUCEMIAREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING A PIRAZOLE-O-GLUCOSIDE DERIVATIVE OF FORMULA (I), IN COMBINATION WITH A DPP IV INHIBITOR SELECTED FROM SITAGLIPTINE, VIDAGLIPTIN, SAXAGLIPTIN, [2-DENAGLIPTIN-1, [2-ALOGLIPTIN] 2- (5-METHYL-2-PHENYLOXAZOLE-4-IL) ETHYLAMINE] ACETYL} PYRROLIDIN-2-CARBONITRILE, (2S) -1 - {[1,1-DIMETHYL-3- (4-PYRIDIN-3-ILIMIDAZOLE- 1-IL) PROPYLAMINO] ACETYL} PYRROLIDIN-2-CARBONITRILE; (S) -1 - ((2S, 3S, 11bS) -2-AMINO-9,10-DIMETOXY-1,3,4,7,11b-HEXAHYDRO-2H-PYRIDO [2,1-a] ISOQUINOLIN-3 -IL) -4-FLUOROMETHYLPYRROLIDIN-2-ONA; AMONG OTHERS. SAID COMPOUND OF FORMULA (I) HAS THE FOLLOWING SUBSTITUENTS: R1 IS ALCOXI C1-3; L1 AND L2 ARE H OR F AND R6 IS H, (C1-3 ALKYL) CARBONYL, (C1-6 ALKYL) OXYCARBONYL, PHENYLOXYCARBONYL, BENZYLOXYCARBONYL OR BENZYLCARBONYL. SUCH COMPOSITION IS ADEQUATE FOR THE TREATMENT OR PREVENTION OF ONE OR MORE SELECTED CONDITIONS OF TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, ABNORMAL GLUCOSE TOLERANCE, ABNORMAL BLOOD GLUCOSE IN FASTING AND HYPERGLYCEMIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07114461 | 2007-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090987A1 true PE20090987A1 (en) | 2009-08-14 |
Family
ID=39870441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001380A PE20090987A1 (en) | 2007-08-16 | 2008-08-14 | PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR068102A1 (en) |
CL (1) | CL2008002424A1 (en) |
PE (1) | PE20090987A1 (en) |
TW (1) | TW200918078A (en) |
UY (1) | UY31290A1 (en) |
WO (1) | WO2009022009A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
TW200900094A (en) | 2007-03-13 | 2009-01-01 | Takeda Pharmaceutical | Solid preparation |
CL2008002427A1 (en) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus. |
CL2008003653A1 (en) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition. |
AR071175A1 (en) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO |
PE20100156A1 (en) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | NAFLD TREATMENT |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP2012512848A (en) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Salt forms of organic compounds |
EA022349B1 (en) | 2009-02-13 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and a further antidiabetic agent and uses thereof |
BR112012012641A2 (en) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-lVTAL INHIBITORS LIKE LINAGLIPTIN |
CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
AU2011268940B2 (en) | 2010-06-24 | 2015-05-21 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
UY33937A (en) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
JP4424203B2 (en) * | 2002-04-26 | 2010-03-03 | 味の素株式会社 | Diabetes prevention and treatment |
DK1638970T3 (en) * | 2003-06-20 | 2011-01-03 | Hoffmann La Roche | Pyrid (2,1-A) -isoquinoline derivatives as DPP-IV inhibitors |
PL1753748T3 (en) * | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
BRPI0516340A (en) * | 2004-10-12 | 2008-09-16 | Glenmark Pharmaceuticals Sa | compound, pharmaceutical composition, method for treating a condition that is regulated or normalized via dpp-iv inhibition, method for treating a metabolic disorder, method for treating type ii diabetes, method for lowering blood glucose, method for treating and prophylaxis of a disease, method for treating undamaged insulin-resistant glucose tolerance, method for the manufacture of a pharmaceutical composition and process for the preparation of compounds |
UY29694A1 (en) * | 2005-07-28 | 2007-02-28 | Boehringer Ingelheim Int | METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO |
EP1942898B2 (en) * | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
PE20080251A1 (en) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
WO2007148185A2 (en) * | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
CL2008000133A1 (en) * | 2007-01-19 | 2008-05-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND |
-
2008
- 2008-08-14 UY UY31290A patent/UY31290A1/en not_active Application Discontinuation
- 2008-08-14 PE PE2008001380A patent/PE20090987A1/en not_active Application Discontinuation
- 2008-08-14 CL CL2008002424A patent/CL2008002424A1/en unknown
- 2008-08-15 WO PCT/EP2008/060739 patent/WO2009022009A1/en active Application Filing
- 2008-08-15 AR ARP080103594A patent/AR068102A1/en unknown
- 2008-08-15 TW TW097131316A patent/TW200918078A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009022009A1 (en) | 2009-02-19 |
TW200918078A (en) | 2009-05-01 |
CL2008002424A1 (en) | 2009-09-11 |
AR068102A1 (en) | 2009-11-04 |
UY31290A1 (en) | 2009-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090987A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE | |
AR064969A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A PIRAZOL DERIVATIVE -OR- GLUCOSIDE | |
AR083679A1 (en) | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | |
UY27518A1 (en) | NEW PIRROLIDINE DERIVATIVES | |
UY31291A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO | |
AR062111A1 (en) | DERIVATIVES OF BETA-D-GLUCOPIRANOSIL INDOL, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTI-DIABETIC AGENTS. | |
ECSP109977A (en) | Pharmaceutical composition comprising a benzene derivative substituted with glucopyranosyl. | |
UY27666A1 (en) | NEW DERIVATIVES OF PIRIDINA AND QUINOLINA | |
UY31295A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDED BY AN SGLT2 INHIBITOR | |
PE20110841A1 (en) | CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-THENYLMETHYL] BENZENE HEMIHYDRATE | |
ECSP066653A (en) | DERIVATIVES OF BENCENOSULFONILAMINO-PIRIDIN-2-IL AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 (II-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | |
AR067538A1 (en) | INHIBIDORTES OF THE 11 BETA -HYDROXIESTEROID-DEHYDROGENase | |
AR067770A1 (en) | DERIVATIVES OF TIAZOL AND DITIAZOL FOR THE TREATMENT OF DIABETES | |
EA201001595A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
CL2011001027A1 (en) | Compounds derived from 1- (benzo [d] [1,3] dioxol-6-yl] -n (1h-indol-5-yl) cyclopropane carboxamide; abc modulators; pharmaceutical composition comprising them; in vitro method of increasing abc transporters; pharmaceutical kit; and its use in the treatment of cystic fibrosis, metabolic problems, of the snc, among others. | |
AR064736A1 (en) | GPCR AGONISTS | |
NO20055680L (en) | Hexahydropyridoisoquinolines as DPP-IV inhibitors | |
PE20110060A1 (en) | CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE | |
CL2009001059A1 (en) | Compounds derived from substituted 1,3-oxazin-2-one-3.6, inhibitors of the activity of 11-beta-hydroxysteroid dehydrogenase i; pharmaceutical composition that includes them; Useful in the treatment of diseases such as diabetes mellitus, among others. | |
ATE442349T1 (en) | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | |
ECSP099037A (en) | METABOLISM MODULATORS AND TREATMENT OF METABOLIC DISORDERS | |
PE20110288A1 (en) | DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANE-2,3,4-TRIOL | |
PE20091425A1 (en) | AMINOTIAZOLE DERIVATIVES | |
AR039281A1 (en) | STABILIZING BLENDS | |
ATE427926T1 (en) | CYCLOALKYLAMIN DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |